Approval · Notice of Compliance 8187 · 2006
ADVATE: Notice of Compliance 8187
Issued July 31, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8187
- Date
- July 31, 2006
- Company
- Baxter Healthcare CorporationDeerfield, Illinois, United States
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Therapeutic class
- Hemostatic agent
Products in this notice
Medicinal ingredients
- RECOMBINANT ANTIHEMOPHILIC FACTOR 250 UNIT per VIAL
- RECOMBINANT ANTIHEMOPHILIC FACTOR 500 UNIT per VIAL
- RECOMBINANT ANTIHEMOPHILIC FACTOR 1,000 UNIT per VIAL
- RECOMBINANT ANTIHEMOPHILIC FACTOR 1,500 UNIT per VIAL